Document:

Letter Agreement

 Exhibit 10.1 
  
 07 May 2009 
 WARNER CHILCOTT COMPANY, LLC 
 P.O.Box 1005 
 Fajardo 
 Puerto Rico 
 00738 
 Terms for exchanging the LEO 80185 Body Indication with a New LEO Product 
 Reference is made to the Master Agreement dated as of April 1, 2003 between Galen (Chemicals) Limited and LEO Pharma A/S (“LEO”) (the “Master Agreement”) as amended by Addendum I dated as of September 14, 2005
between Warner Chilcott Company, LLC (formerly Warner Chilcott Company, Inc.) (“WCCI”) and LEO (the “Addendum”) and to the License, Supply and Development Agreement dated as of September 14, 2005 between LEO and WCCI, as
amended (the “DC Agreement”). In consideration of the covenants and agreements contained herein and notwithstanding anything to the contrary set forth in the Master Agreement, the Addendum and the DC Agreement, LEO and WCCI hereby agree as
follows: 
 Whereas WCCI has expressed its interest in marketing a new LEO product described in Exhibit A hereto (the “New Product”) in the the
Territory (as defined in the DC Agreement) instead of LEO 80185 (trunk indication) for the topical treatment of psoriasis vulgaris in adults described in Appendix IV to the DC Agreement (the “80185 Product”); and 
 Whereas LEO has agreed to attempt to develop such New Product. 
 Now
therefore WCCI and LEO have agreed to enter into this Letter Agreement. 

 LEO and WCCI agree that: 
  

	 	1.	LEO shall cease development of the 80185 Product for the Territory until such time as it delivers the 80185 Development Resumption Notice (as defined below) to WCCI in accordance
with the terms hereof. 

  

	 	2.	LEO will develop the New Product for the Territory on the following conditions: 

  

	 	a.	Between January 1, 2010 and December 1, 2010 LEO shall deliver written notice to WCCI providing that (i) LEO will continue the development of the New Product for the
Territory (such notice, the “New Product Development Notice”) or (ii) LEO will resume the development of the 80185 Product for the Territory and will terminate its development hereunder with respect to the New Product (such notice,
the “80185 Development Resumption Notice”), it being understood that such election of whether to continue the New Product development or resume the 80185 Product development shall be determined in LEO’s sole discretion.

  

	 	b.	If LEO delivers a New Product Development Notice in accordance with Section 2(a) hereof the parties shall execute an amendment to Appendix IV of the DC Agreement on or prior to
January 15, 2011 deleting the 80185 Product and including the New Product as an Appendix IV Product (as defined in the DC Agreement) and WCCI shall pay the following milestones to LEO: 

  

	 	i.	USD 25,000,000 (United States Dollars twenty five million) no later than January 15, 2011; 

  

	 	ii.	USD 10,000,000 (United States Dollars ten million) 15 (fifteen) days after the acceptance for filing of an NDA or an sNDA for the approval of the New Product with the United States
Food and Drug Administration (the “FDA”); and 

  

	 	iii.	USD 15,000,000 (United States Dollars fifteen million) 15 (fifteen) days after the approval by the FDA of the New Product for the Territory. 

 For the avoidance of doubt, if LEO delivers the 80185 Development Resumption Notice in accordance with Section 2(a) hereof then the milestone payments relating to
the 80185 
  

 2 

 Product set forth in Article 5 of the Addendum (in the Addendum referred to as the “LEO 80185 – Trunk
Indication”) shall be payable to LEO, subject to provisions of the Addendum. 
  

	 	3.	As promptly as practicable, LEO will use commercially reasonable efforts to file and diligently prosecute one or more patent applications covering the New Product and any patents
issuing thereon shall be deemed to be “Patents” under the terms of the DC Agreement. 

  

	 	4.	It is understood that none of the milestone payments paid according to this Letter Agreement are refundable. 

  

	 	5.	Subject to the terms of the DC Agreement, all rights including, but not limited to, any intellectual property rights, arising out of the development of either the 80185 Product and
the New Product will be owned by LEO. 

  

	 	6.	LEO does not guarantee that it succeeds in developing a New Product or that an NDA, an sNDA and/or a marketing authorization can be obtained for any of the indications/products
referred to in this Letter Agreement. 

  

	 	7.	The provisions of the Master Agreement, the Addendum and the DC Agreement shall, to the extent such provisions are not changed by this Letter Agreement, remain unchanged and in full
force and effect. 

  

 3 

 Please indicate your acceptance of the foregoing by executing and returning one of the duplicate original copies of this
document to the undersigned at the address set forth above. 
 LEO PHARMA A/S 
  

											
	 /s/    Gitte P. Aabo
	 		 	 /s/    Lars Olsen
	  		  		  	
	Gitte P. Aabo	 		 	Lars Olsen	  		  		  	
	President, CEO	 		 	Executive Vice President	  		  		  	

  

							
		 		 	Acknowledged and agreed:
			
		 		 	WARNER CHILCOTT COMPANY, LLC
				
		 		 	By:	 	 /s/    Max A. Torres

		 		 	Name: Max A. Torres
		 		 	Title: Senior Director

  

 4Settlement and License Agreement

 Exhibit 10.2 
 SETTLEMENT AND LICENSE AGREEMENT 
 This is an agreement (hereinafter referred to as
“Agreement”) dated as of this 9th day of January, 2009, by and among Warner Chilcott Company, Inc. (“WCCI”), a corporation organized and existing under the laws of Puerto Rico, and Watson Pharmaceuticals, Inc.
(“WPI”), a corporation organized and existing under the laws of the State of Nevada, and Watson Laboratories, Inc. (“WLI”, and, together with WPI, “Watson”), a corporation organized and existing
under the laws of the State of Nevada. WCCI and Watson are sometimes individually referred to herein as a “Party” and collectively referred to herein as “Parties.” 
 WHEREAS, the Parties are presently involved in the Lawsuit, in which it has been asserted that Watson infringes certain claims of U.S. Patent
No. 5,552,394 (the “Patent” and the asserted claims therein, the “Patent Claims”), with respect to certain of which Patent Claims Watson has asserted affirmative defenses and counterclaims alleging invalidity,
unenforceability and/or non-infringement; and 
 WHEREAS, the Parties wish to fully settle the Lawsuit concerning the Patent Claims with
respect to the Watson Product upon the terms and subject to the conditions set forth below. 
 NOW, THEREFORE, in consideration of the mutual
promises and covenants contained in this Agreement and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows: 
 1. The following terms, when used with initial capital letters shall have the meaning set forth below. 
 a. “Affiliate” shall mean with respect to a Party, any Person that directly or indirectly, through one or more
intermediaries, controls, is controlled by, or is under common control with, such Party at any time during the period for which the determination of affiliation is being made. For the purposes of this definition, “control”
(including the terms “controlled by” and “under common control with”) means the possession, directly or indirectly, of the power to direct or cause the direction of the management, policies or affairs of a person,
whether through ownership of voting securities or general partnership or managing member interests, by contract or otherwise, including the ownership, directly or indirectly, of securities having the power to elect a majority of the board of
directors or similar body governing the affairs of such person. Without limiting the generality of the foregoing, a person shall be deemed to control any other person in which it owns, directly or indirectly, a majority of the voting interests.

 b. “ANDA” shall mean an Abbreviated New Drug Application as defined under 21 U.S.C. § 355(j).

 c. “FDA” shall mean the United States Food and Drug Administration. 
 d. “Launch Date” shall mean the earliest of (i) January 22, 2014, (ii) the date of a final, nonappealable
judicial order that the Patent is invalid, unenforceable or not infringed by a Third Party’s generic version of the WCCI Product and (iii) the date on which Watson is licensed under Paragraph 7 to launch. 

 e. “Lawsuit” shall mean Warner Chilcott Company, Inc. v. Watson
Pharmaceuticals, Inc. and Watson Laboratories, Inc., 2:06-CV-03491, U.S. District Court for the District of New Jersey. 
 f. “Losses” shall mean all pending and potential claims, demands, all manner of actions, causes of action, suits, debts, liabilities, losses, damages, attorneys’ fees, costs, expenses, judgments, settlements, interest,
punitive damages and other damages or costs of whatever nature, whether known or unknown, pending or future, certain or contingent. 
 g. “Person” means any individual, corporation, association, partnership (general or limited), joint venture, trust, estate, limited liability company, limited liability partnership, unincorporated organization, government
(or any agency or political subdivision thereof) or other legal Person or organization. 
 h. “Proceeding”
shall mean any action, audit, litigation, investigation, suit or other proceeding. 
 i. “Related Parties”
shall mean a Party’s Affiliates, directors, officers, employees, agents, representatives, heirs, assigns, predecessors, successors or other related parties. 
 j. “Third Party” shall mean any Person other than a Party or its Affiliates. 
 k. “Watson Product” shall mean the oral contraceptive drug that is described in, and is the subject of, ANDA
No. 78-267 or any other ANDA filed by Watson or its Affiliates for which the WCCI Product is the reference product. 
 l.
“WCCI NDA” shall mean New Drug Application (an “NDA”) No. 021871. 
 m. “WCCI Product” shall mean the oral contraceptive drug that is described in, and is the subject of the WCCI NDA, which is currently marketed by WCCI under the trademark Loestrin® 24 Fe. 
 2. Upon the terms and subject to the conditions
of this Agreement, in consideration of the mutual execution of this Agreement and the mutual agreement to be legally bound by the terms hereof, each Party, on behalf of itself and its Related Parties, hereby releases, acquits and forever discharges
each other Party and its Related Parties from any and all Losses arising out of, derived from, predicated upon or relating to the Patent Claims, the actions asserting such Patent Claims and the Lawsuit; provided, however, nothing in
this Agreement shall prevent or impair the right of any Party to bring a Proceeding in court or any other forum for a breach of this Agreement or any representation, warranty or covenant herein. Notwithstanding this release or anything herein to the
contrary, nothing herein shall preclude Watson from challenging the validity, enforceability and/or infringement of the Patent in any future litigation concerning a product other than (i) the Watson Product, or (ii) any other product that,
as designed, could be AB rated to the WCCI Product. The Parties agree to the entry of a dismissal without prejudice of the Lawsuit, with each side bearing its own costs and attorneys’ fees. Promptly following the 

  

 2 

 
execution of this Agreement, the Parties shall cause to be filed with the United States District Court for the District of New Jersey, all necessary papers,
including a Stipulation of Dismissal, attached as Attachment A, required to dismiss all claims and counterclaims, motions, and petitions asserted in the Lawsuit and shall take all other necessary actions to obtain the settlement and dismissal of the
Lawsuit. 
 3. Each Party acknowledges and agrees that: 
 a. It may have sustained Losses that are presently unknown and unsuspected, and that such Losses might give rise to Losses in the future.
Nevertheless, each Party acknowledges and agrees that this Agreement has been negotiated and agreed upon, notwithstanding the existence of such possible Losses, all of which have been hereby released under Paragraph 2 hereof. 
 b. If any fact relating to this Agreement or the Lawsuit and now believed to be true is found hereafter to be other than, or different
from, that which is now believed, each Party expressly assumes the risk of such difference in fact and agrees that this Agreement shall be, and will remain, effective notwithstanding any such difference in fact, subject to each Party’s right to
bring a Proceeding for a breach of this Agreement or any representation, warranty or covenant herein. 
 c. This Agreement may
be pleaded as a full and complete defense to, and used as a basis for injunction against, any Proceeding that may be instituted, prosecuted or attempted in breach hereof. Should any Party institute a Proceeding to enforce any provision of this
Agreement, or for Losses by reason of any alleged breach of any provision hereof, or for a declaration of such Party’s rights or obligations hereunder, or for any other judicial remedy predicated upon the breach by the other Party of this
Agreement or as may otherwise be permitted hereunder, the prevailing Party shall be reimbursed by the losing Party for all reasonable and necessary costs and expenses incurred thereby, including, but not limited to, reasonable attorneys’ fees
for the services rendered to the Party finally prevailing in any such Proceeding. 
 4. Watson covenants and agrees that it shall not sell
the Watson Product prior to January 22, 2014 or such earlier date upon which it is licensed to sell the Watson Product pursuant to Paragraphs 5, 7 or 8 hereof. Watson agrees that to the extent that Watson or its Affiliates sells, has sold, or
offers for sale any Watson Product in the United States in violation of this Paragraph 4, such breach will cause irreparable harm to WCCI. Watson hereby irrevocably and unconditionally consents to immediate entry of a temporary restraining order,
preliminary injunction and permanent injunction, without the requirement to post a bond, to enforce the provisions of this Paragraph 4. 
 5.
WCCI covenants and agrees that neither it nor its Affiliates shall market or supply, or grant a Third Party any rights (under the Patent or otherwise) to market a generic version of the WCCI Product, whether manufactured under the WCCI NDA or an
ANDA, on any date prior to the date that is one hundred eighty (180) days following the Launch Date, unless WCCI agrees to establish an early launch date for Watson that is at least one hundred eighty (180) days prior to the commencement
of marketing by WCCI, its Affiliates or such Third Party (an “Early Launch  

  

 3 

 
Date”). Any authorization of or license to a Third Party by WCCI to market the WCCI Product in which WCCI assigns or transfers the exclusive
right to market the WCCI Product shall not trigger this provision, so long as such authorization or license is subject to the terms and conditions of this Agreement. WCCI shall, to the extent reasonably practicable, provide Watson with 60 days’
advance written notice of any such Third Party sale or license. For the avoidance of doubt, nothing in this Paragraph 5 shall prevent WCCI and its Affiliates from marketing or from supplying, authorizing or licensing a Third Party to market a
generic version of the WCCI Product, so long as such product is not sold commercially until the day that is one hundred eighty (180) days following the Launch Date or the Early Launch Date. 
 6. Upon the terms and subject to the conditions of this Agreement, WCCI grants to Watson a non-exclusive, fully paid-up, worldwide, royalty-free,
irrevocable license, under the Patent and all regulatory exclusivities pertaining to and covering the WCCI Product, to manufacture and offer for sale in the United States commencing prior to January 22, 2014 for sale commencing on
January 22, 2014, and to sell effective January 22, 2014 and thereafter, the Watson Product, all for the terms of such Patent and regulatory exclusivities. WCCI shall use its commercially reasonable efforts to cooperate with Watson, at
Watson’s sole cost and expense, as may be required to obtain FDA approval of Watson’s ANDA No. 78-267 effective January 22, 2014. 
 7. If a Third Party commercially launches a generic version of the WCCI Product without authorization from WCCI, then WCCI shall grant to Watson the license granted pursuant to Paragraph 6 hereof, effective on the
same date as such Third Party launch. Further provided, in the event a Third Party commercially launches a generic version of the WCCI Product and WCCI subsequently succeeds in having such Third Party cease its sales of such product, then the
license granted pursuant to this Paragraph 7 shall be suspended at such time as the Third Party product is no longer commercially available or, if such cessation of sales is pursuant to an injunction issued by a court, the date of such injunction,
whichever is earlier, and the license shall be reinstated upon the subsequent occurrence, if any, of an “at risk” launch as described in the first sentence of this Paragraph 7. WCCI shall use its commercially reasonable efforts to
cooperate with Watson, at Watson’s sole cost and expense, as is required to obtain FDA approval of Watson’s ANDA No. 78-267 under a license granted pursuant to this Paragraph 7. 
 8. If a Third Party obtains a final, nonappealable judicial order that the Patent is invalid, unenforceable or not infringed by a Third Party’s
generic version of the WCCI Product, then WCCI shall grant to Watson a non-exclusive license under the Patent so adjudicated and all regulatory exclusivities to enter the market with the Watson Product at the time of such order, and WCCI shall use
its commercially reasonable efforts to cooperate with Watson, at Watson’s sole cost and expense, as may be required to obtain FDA approval of Watson’s ANDA No. 78-267 at or as soon as practicable after such order. For clarity, if the
Patent is found in a final, nonappealable judicial order to be invalid, unenforceable or not infringed by a Third Party’s generic version of the WCCI Product, Watson shall be entitled to exercise all rights with respect to the Patent to the
extent any Third Party would legally be able to do so. 
 9. All rights not expressly granted to Watson under Paragraphs 6, 7 and 8 are
expressly reserved to WCCI. Watson expressly disclaims any right to use the WCCI Product, Patent or Patent Claims except in accordance with the express grants hereunder, and WCCI has no 

  

 4 

 
obligation to make available any intellectual property rights or to take any other actions other than as expressly set forth herein; provided,
however, that WCCI shall not use or sue or bring a Proceeding seeking to enforce any of the Patent or Patent Claims or any other intellectual property rights pertaining to the WCCI Product to prevent or restrict Watson or its Affiliates,
licensees, sublicensees or subcontractors from undertaking the licensed activities permitted under this Agreement, so long as all such activities comply in all material respects with the terms contained herein. 
 10. Notwithstanding anything to the contrary contained in this Agreement, Watson may grant sublicenses in order to exercise its rights and carry out its
obligations under this Agreement: (a) to its Affiliates, without the prior written consent of WCCI; and (b) to third parties, with WCCI’s prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed.
Watson acknowledges that the grant of a sublicense or use of a subcontractor shall not relieve Watson from, and Watson shall remain responsible for, all of its obligations under this Agreement. Watson shall be responsible for the compliance of its
Affiliates, sublicensees and subcontractors with this Agreement. 
 11. Each Party hereto represents and warrants to the other Party that, as
of the date hereof: 
 a. this Agreement is a legal, valid and binding obligation of the warranting party, enforceable against
such party in accordance with its terms, except as enforcement may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally or by general principles of equity; 
 b. the warranting party is not subject to any judgment, order, injunction, decree or award of any court, administrative agency or
governmental body that would or might interfere with its performance of any of its material obligations hereunder; and 
 c.
the warranting party has full power, right and authority to enter into and perform its obligations under this Agreement in accordance with its terms. 
 12. WCCI represents and warrants that, as of the date hereof: 
 a. it presently owns,
licenses or has the legal rights to use the Patent and the WCCI NDA, and to grant the licenses hereunder, and that it has the right to settle the Lawsuit; and 
 b. it has no pending patent applications claiming the WCCI Product. 
 13. EXCEPT AS EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY
OPERATION OF APPLICABLE LAW. 
 14. Neither Party hereto may assign any of its rights or obligations under this Agreement without the prior
written consent of the other Party, except to an Affiliate, or in connection with a merger, reorganization, change of control or sale of all or substantially all of the applicable business. Notwithstanding the foregoing, Watson may assign
this Agreement to any successor- 

  

 5 

 
in-interest to the Watson Product, whether by merger, asset sale, operation of law or otherwise. Any purported assignment in violation of the foregoing shall
be null and void ab initio and of no force or effect. No assignment of this Agreement will relieve the assigning Party from any of its obligations hereunder. In the event of a permitted assignment, this Agreement shall be binding upon and
inure solely to the benefit of the Parties and their respective successors and permitted assigns. 
 15. For avoidance of doubt, all rights
and licenses granted under or pursuant to any paragraph of this Agreement are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code (the “Bankruptcy Code”), licenses of
“intellectual property” as defined under the Bankruptcy Code. The Parties shall retain and may fully exercise all of their respective rights and elections under the Bankruptcy Code; provided, however, that should WCCI become
a party to a bankruptcy proceeding and such proceeding is not dismissed within thirty (30) days then, to the extent permitted by law, this Agreement and the licenses granted by WCCI hereunder shall be adopted by any bankruptcy trustee or
relevant Third Party charged with the disposition of same, and shall not be rejected by same, it being the Parties’ intent that, in such event, Watson and its Affiliates and sublicensees shall be entitled to retain the rights granted to them
hereunder by WCCI. Further, upon the bankruptcy of WCCI, Watson shall be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property, and such, if not already in its possession, shall be promptly
delivered to Watson unless WCCI elects to continue, and continues, to perform all of its obligations under this Agreement. 
 16. From the
date hereof until the date on which Watson is permitted to commence sales of the Watson Product hereunder, WCCI will use its reasonable best efforts to provide Watson with 30 days’ advance notice of any proposed labeling changes with respect to
the WCCI Product requested by WCCI or any specific labeling amendments or supplements with respect to the WCCI Product including, but not limited to, any changes made in response to an order or request of the FDA. 
 17. Each Party shall, at its own cost and expense, take all actions and do all things reasonably necessary or proper, including under applicable law, to
make effective and further the intents and purposes of the transactions contemplated by this Agreement, including executing any further instruments reasonably requested by the other Party. 
 18. Each Party acknowledges and agrees that: 
 a. The Mutual Confidential Disclosure Agreement between WPI and WCCI, dated as of November 8, 2007, as amended (the “Confidentiality Agreement”), shall remain in full force and effect, the terms
of which are hereby incorporated by reference, as amended and/or clarified by this Agreement and this Paragraph 18. 
 b. The
Parties hereby acknowledge and agree that (i) WLI agrees to be bound by the terms and conditions of the Confidentiality Agreement as if it were originally a party thereto; (ii) the term of the Confidentiality Agreement is amended such that
it shall not terminate until the tenth anniversary of the date of this Agreement; (iii) the terms of this Agreement and the transactions contemplated hereunder, and any information exchanged hereunder shall be deemed “Confidential
Information” for purposes of the Confidentiality 

  

 6 

 
Agreement and any use or disclosure thereof shall be governed by such agreement; and (iv) the legal department of each Party shall be permitted to
retain one copy of the other Party’s Confidential Information solely for archival purposes, notwithstanding paragraph 3 of the Confidentiality Agreement. Each Party acknowledges that any and all other information provided to it by the other
Party or its representatives concerning such other Party and its Affiliates shall remain subject to the terms and conditions of the Confidentiality Agreement. 
 c. If either Party becomes aware or has knowledge of any unauthorized use or disclosure of the other Party’s Confidential
Information, it shall promptly notify the disclosing Party of such unauthorized use or disclosure. 
 d. Except (i) as
set forth in any press release mutually agreed by the Parties, (ii) as consistent with the press release issued pursuant to this Paragraph 18(d) and (iii) as may be required to be made by a Party to the extent that such disclosure is
legally required including, without limitation, all applicable securities and regulatory laws and regulations, neither Party shall make or allow the publication of any press release or public announcement with respect to this Agreement or any of the
transactions contemplated hereby, without the prior written approval of the other Party, which shall not unreasonably be withheld, conditioned or delayed. 
 19. Each Party shall, at its own cost and expense, take all actions and do all things reasonably necessary or proper, including under applicable law, to make effective and further the intents and purposes of the
transactions contemplated by this Agreement, including executing any further instruments reasonably requested by the other Party. 
 20. This
Agreement (including all attachments hereto) constitutes the entire agreement and understanding between the Parties with respect to the subject matter hereof and supersedes all prior agreements or understandings, oral or written, with respect to
such matters, except for the Confidentiality Agreement, which shall remain in full force and effect as modified hereunder, the terms of which are incorporated by reference. The Parties may amend or modify the provisions of this Agreement,
including this provision, only by mutual agreement in writing. 
 21. The Parties agree and acknowledge that this Agreement is the product of
all of the Parties and shall not be construed against any of the Parties. 
 22. All notices or other communications hereunder shall be
deemed to have been duly given and made if in writing and if served by personal delivery upon a Party, if delivered by registered or certified mail (return receipt requested) or by a reputable overnight express courier service (charges prepaid), or
if sent by facsimile to the person at the address set forth below, or such other address as may be designated in writing hereafter, in the same manner, by such person as follows: 
  

 7 

 In the case of WCCI: 
 Warner Chilcott Company, Inc. 
 Union Street Km. 1.1 
 Fajardo 
 Puerto Rico 
 Facsimile: 787 863 5355 
 Attn: Senior
Director, Business Management 
 with a copy to: 
 Warner Chilcott (US), LLC 
 100 Enterprise Drive 
 Rockaway, NJ 07866 
 Facsimile:
(973) 442-3316 
 Attn: General Counsel 
 In the case of Watson: 
 Watson Pharmaceuticals, Inc. 
 311 Bonnie Circle 
 Corona, California 92880

 Facsimile: (951) 493-5821 
 Attn: General Counsel 
 Such notices will be deemed to have been given on the date delivered in the case of hand delivery or
delivery by overnight courier, on the date set forth in the confirmation sheet in the case of facsimile delivery, and on the fifth (5th) business day following the date of post mark in the case of delivery by mail. 
 23. This Agreement and any dispute arising out of or related to this Agreement shall be governed by and construed in accordance with the laws of the
State of New York. With respect to any Proceeding relating to this Agreement, each Party irrevocably agrees and consents to the exclusive jurisdiction of the federal and state courts in New York and waives any objection to venue of any such
Proceeding brought in any such court. EACH PARTY HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT TO A TRIAL BY JURY IN RESPECT TO ANY SUCH PROCEEDING. 
 24. WCCI shall defend, indemnify and hold harmless each of Watson and its Affiliates and their respective directors, officers and employees (each an
“Indemnified Party”) from and against any reasonable fees, costs or expenses (including expert witnesses and attorneys) incurred by an Indemnified Party in connection with any action, investigation, subpoena, lawsuit or proceeding, whether
formal or informal, civil or criminal, brought by a governmental entity or Third Party against an Indemnified Party (each a “Proceeding”) arising from the Parties’ entering into of this Agreement (each or collectively “WCCI
Liability”). An Indemnified Party claiming a right to indemnification under this Paragraph 24 shall notify WCCI of any Proceeding within five (5) business days after the Indemnified Party has knowledge of such Proceeding. At the 

  

 8 

 
Indemnified Party’s request, WCCI shall use reasonable efforts to cooperate with the Indemnified Party and its legal representatives in the
investigation and defense of any Proceeding. WCCI shall remit and pay any and all WCCI Liability to the respective Indemnified Party on a quarterly calendar year basis; provided that, WCCI’s obligation to reimburse Indemnified Parties for WCCI
Liability shall be limited to one million dollars ($1,000,000) in each calendar year (January 1 through December 31 of each year). For the avoidance of doubt, WCCI shall never be obligated to indemnify Watson and its Affiliates and their
respective directors, officers and employees for WCCI Liability in an amount greater than $1,000,000 in a given year, regardless of the amount of WCCI liability in any other year. 
 25. This Agreement may be executed in any number of counterparts, and execution by each of the Parties of any one of such counterparts will constitute
due execution of this Agreement. Each such counterpart hereof shall be deemed to be an original instrument, and all such counterparts together shall constitute but one agreement. 
 26. If any provision of this Agreement is held invalid, illegal or unenforceable for any reason, the Parties shall negotiate in good faith for a
substitute provision to continue the intent and purpose of such invalid provisions, and the validity, legality and enforceability of the remaining provisions shall not be in any way impaired thereby. 
 [Signature page follows] 
  

 9 

 This Agreement is signed as indicated below by duly authorized representatives of WCCI and Watson,
respectively, effective as of the date first written above. 
  

			
	WARNER CHILCOTT COMPANY, INC.
		
	By:	 	/s/ Max A. Torres
	Name: Max Torres
	Title: Senior Director
	
	WATSON LABORATORIES, INC.
		
	By:	 	/s/ Paul M. Bisaro
	Name: Paul M. Bisaro
	Title: President and Chief Executive Officer
	
	WATSON PHARMACEUTICALS, INC.
		
	By:	 	/s/ Paul M. Bisaro
	Name: Paul M. Bisaro
	Title: President and Chief Executive Officer

 ATTACHMENT A 
 IN THE UNITED STATES DISTRICT COURT 
 FOR THE DISTRICT OF NEW JERSEY 
  

					
	 WARNER CHILCOTT COMPANY, INC.
  
 Plaintiff,
 v.
  
 WATSON PHARMACEUTICALS,
INC.
 and WATSON LABORATORIES, INC.
  
  
 Defendants.
	  	 :
 :
 :
 :
 :
 :
 :
 :
 :
	  	 DOCUMENT ELECTRONICALLY FILED
  
 Civil Action No. 2:06-CV-3491 (HAA(ES))
  
 STIPULATION OF DISMISSAL
 WITHOUT PREJUDICE

  
 Pursuant to Rules 41(a)(1)
and 41(c) of the Federal Rules of Civil Procedure. The Plaintiff and Defendants, by their undersigned attorneys, hereby stipulate and agree that the above captioned action, including all claims, counterclaims and affirmative defenses, are dismissed
without prejudice. 
 Each party will bear its own costs, disbursements and attorneys’ fees. 
  

 2 

					
	Dated:                             , 2008
	 		 	Respectfully submitted,
			
	 	 		 	  
	 Of Counsel:
 Robert D. Bajefsky, Esq.
 Rebecca D. Hess, Esq.
 William Strauss, Esq.
 FINNEGAN, HENDERSON, FARABOW,
     GARRETT & DUNNER,
L.L.P.
 901 New York Avenue, N.W.
 Washington, D.C. 20001-4413

 Tel.: (202) 408-4000
 Fax: (202) 408-4400
	 		 	 Kevin J. McKenna, Esq.
 Elvin Esteves, Esq.

GIBBONS P.C.
 One Gateway Center
 Newark, NJ 07102-5310
 Tel.: (973) 596-4500
 Fax: (973) 596-0545
 Email: kmckenna@gibbonslaw.com
  
 Attorneys for Plaintiff Warner Chilcott Company, Inc.

			
	 	 		 	  
	 Of Counsel:
 Steven J. Lee, Esq.
 Charles A. Weiss, Esq.
 Michael A. Freno, Esq.
 Melissa Alegre, Esq.
 KENYON & KENYON L.L.P.
 1 Broadway
 New York, NY 10004-1007
 Tel.: (212) 425-7200
 Fax: (212) 425-5288
	 		 	 Glenn D. Curving, Esq.
 Joshua S. Bratspies,
Esq.
 RIKER, DANZIG, SCHERER, HYLAND
     & PERRETTI LLP
 Headquarters Plaza
 One Speedwell Avenue
 Morristown, NJ 07962-1981
 Tel.:
(973) 538-0800
 Fax: (973) 538-1984
  
 Attorneys for Defendants Watson Pharmaceuticals, Inc. and Watson Laboratories, Inc.

  

 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00161-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00161-of-00352.parquet"}]]